2C-O-22

2C-O-22
Clinical data
Other names4-(2,2,2-Trifluoroethoxy)-2,5-dimethoxyphenethylamine; 2,5-Dimethoxy-4-(2,2,2-trifluoroethoxy)phenethylamine
Routes of
administration		Oral[1][2]
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of actionUnknown[1]
Identifiers
  • 2-[2,5-dimethoxy-4-(2,2,2-trifluoroethoxy)phenyl]ethanamine
PubChem CID
Chemical and physical data
FormulaC12H16F3NO3
Molar mass279.259 g·mol−1
3D model (JSmol)
  • COC1=CC(=C(C=C1CCN)OC)OCC(F)(F)F
  • InChI=1S/C12H16F3NO3/c1-17-9-6-11(19-7-12(13,14)15)10(18-2)5-8(9)3-4-16/h5-6H,3-4,7,16H2,1-2H3
  • Key:WXMPTDDEIHHBRM-UHFFFAOYSA-N

2C-O-22, also known as 4-(2,2,2-trifluoroethoxy)-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and 2C families.[1][2][3] According to Daniel Trachsel, 2C-O-22 produced potential threshold effects at a dose of 42 mg plus 15 mg orally, with Trachsel listing its dose as 57 mg or more.[1][2] The drug's duration is unknown and its effects were not further described.[1][2] The receptor interactions of 2C-O-22 have been studied, with it having been found to act as a serotonin 5-HT2A receptor agonist among other actions.[3] 2C-O-22 was first described in the scientific literature by Trachsel in 2012.[2][1] It is a controlled substance in Canada under phenethylamine blanket-ban language.[4]

See also

References

  1. ^ a b c d e f Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. pp. 782, 784. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
  2. ^ a b c d e Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819. A single experiment with 42 + 15 mg of 49 revealed this level to be a potential threshold dose.
  3. ^ a b Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2019). "Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines". Frontiers in Pharmacology. 10 1423. doi:10.3389/fphar.2019.01423. PMC 6893898. PMID 31849671.
  4. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.